tailieunhanh - Báo cáo y học: "NF-κB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: NF-κB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor. | Available online http content 9 5 R97 Research article NF-kB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATcI in mouse arthritis without affecting expression of RANKL osteoprotegerin or macrophage colony-stimulating factor Tetsuo Kubota1 Machiko Hoshino1 Kazuhiro Aoki2 Keiichi Ohya2 Yukiko Komano3 Toshihiro Nanki3 Nobuyuki Miyasaka3 and Kazuo Umezawa4 Department of Microbiology and Immunology Tokyo Medical and Dental University Graduate School of Health Sciences Tokyo Japan department of Hard Tissue Engineering Tokyo Medical and Dental University Graduate School Tokyo Japan 3Department of Medicine and Rheumatology Tokyo Medical and Dental University Graduate School Tokyo Japan department of Applied Chemistry Keio University Kanagawa Japan Corresponding author Tetsuo Kubota Received 13 Jun 2007 Revisions requested 9 Aug 2007 Revisions received 25 Aug 2007 Accepted 25 Sep 2007 Published 25 Sep 2007 Arthritis Research Therapy 2007 9 R97 doi ar2298 This article is online at http content 9 5 R97 2007 Kubota et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Open Access Abstract Inhibition of NF-kB is known to be effective in reducing both inflammation and bone destruction in animal models of arthritis. Our previous study demonstrated that a small cell-permeable NF-kB inhibitor dehydroxymethylepoxyquinomicin DHMEQ suppresses expression of proinflammatory cytokines and ameliorates mouse arthritis. It remained unclear however whether DHMEQ directly affects osteoclast precursor cells to suppress their differentiation to mature osteoclasts in vivo. The effect of DHMEQ on human osteoclastogenesis also .